Virtual Library
Start Your Search
Y. Chen
Author of
-
+
P2.05 - Poster Session with Presenters Present (ID 463)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.05-046 - Is Delineating Clinical Target Volume a Must for Medium and Late Stages of Non-Small Cell Lung Cancer? (ID 5940)
14:30 - 14:30 | Author(s): Y. Chen
- Abstract
Background:
The main reason for a low progression-free survival rate in radiotherapy for NSCLC is that the lung is sensitive to radiation, and radiation-induced lung injury is closely related to the exposed volume of the lung tissues. A large irradiation field resulted in difficulty in increasing target dose, so clinically complete remission is very difficult in the primary lesion of the lung cancer. Therefore, as opinions are currently divided on whether it is necessary to delineate the CTV, this study aimed to study the impact of delineating CTV on the treatment of lung cancer.
Methods:
A total of 177 patients with medium and late stages of NSCLC diagnosed by pathology and/or cytology were selected. These patients received three-dimensional conformal radiation therapy (3-DCRT) or intensity modulated radiation therapy (IMRT) were divided into an undelineated CTV group (A group) and delineated CTV group (B group). Gross tumor volume (GTV) and planning target volume (PTV) were delineated in the A group, while CTV was additionally delineated in the B group. Dose was fractionated in pulmonary lesions in the two groups: 200-220 cGy/time, 5 times per week, and the radiation dose was DT5600- 6600 cGy.The mean lung tumor doses were comparable between the two groups.
Results:
The short-term overall response rate had a trend to be higher in group B, while the 1-year, 2-year and 3-year distant metastasis rates, progression-free survival and overall survival rates had a trend to be higher in group A, but none of the differences were significant. The incidence of radiation pneumonitis was higher in group B (33.33% vs. 16.30%, P=0.017), but none were Grade-4 or worse.
Conclusion:
Undelineating the CTV in radiotherapy of lung tumors tends to reduce the radiation field and significantly reduce the incidence of radiation pneumonitis, but it don’t reduce overall response rate, the progression-free survival and overall survival rate.
